June 21, 2013

Randomized Controlled Trial of High-Dose Intradermal Versus Standard-Dose Intramuscular Influenza Vaccine in Organ Transplant Recipients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Influenza vaccine is recommended for transplant recipients annually. There are several types of influenza vaccines on the market now including standard intramuscular, adjuvanted intramuscular and intradermal. An advantage of giving flu vaccine intradermally is to take advantage of the abundant Langerhans/dendritic cells at the site that act as potent antigen presenting cells. Baluch et al. conducted a RCT of 229 SOT recipients and randomized them to receive intramuscular or intradermal vaccine. The study showed no significant difference between the two strategies with regards to immunogenicity of the vaccines, but the intradermal strategy appeared to be better for the influenza B component of the vaccine if lung transplants were excluded. The study provides important data for the use of intradermal vaccines in transplant patients and suggests that this vaccine could be used as an alternative to intramuscular vaccination.

Cardiac Transplantation, Intestinal Transplantation, Liver Transplantation, Lung Transplantation, Pancreas Transplantation, Renal Transplantation, Transplant Infectious Disease

Tags: ,